Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease
IRAPID: Infliximab Infusion Rate in Pediatric Inflammatory Bowel Disease. a Randomized Non-inferiority Trial of Infusion Reactions with Infliximab Infusion-rates of 30 Minutes and 60 Minutes
University Hospital, Akershus
60 participants
Feb 1, 2025
INTERVENTIONAL
Conditions
Summary
OBJECTIVES OF THE STUDY 1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min. 2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min. 3. Investigate resource use in terms of total length of stay and use of nursing resources.
Eligibility
Inclusion Criteria3
- Pediatric IBD patients on infliximab
- years
- Received at least 5 infusions of infliximab prior to entry in the study
Exclusion Criteria5
- Receiving infliximab for non-IBD condition (reumatological or other causes)
- previous severe infliximab infusion reaction
- need for an interpreter
- heart failure with hemodynamic impact
- unwillingness to participate
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Infusion reactions of infliximab is compared between 30 and 60 minutes infliximab infusion-rates.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06839820